异动解读|ImmunityBio盘中下跌4.14%,第三季度亏损扩大且营收不及预期持续压制股价

行情直击
Nov 16

11月16日,ImmunityBio盘中下跌4.14%,报6.05美元/股,成交额973.46万美元。

消息面上,市场仍在消化公司此前披露的第三季度业绩不及预期影响,亏损扩大与营收逊于预期继续压制股价表现。

数据显示,公司第三季度营收4884.1万美元,虽高于上年同期的3210万美元,但低于市场预期的5925万美元;每股净亏损0.18美元,上年同期亏损0.07美元,也明显差于预期。尽管Anktiva在以色列获批、欧洲推进及膀胱癌试验达成主要终点,但仍未扭转市场对财务表现和商业化执行的担忧。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10